Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ Научный центр психического здоровья РАМН, Москва
Список исп. литературыСкрыть список 1. Иванов С.В. Терапия психосоматических расстройств. В кн.: Психические расстройства в клинической практике. Под ред. акад. РАМН А.Б.Смулевича. М., 2011; с. 441–607. 2. Смулевич А.Б. Депрессии при соматических и психических заболеваниях. М., 2007. 3. Azoulay L, Yin H, Renoux C, Suissa S. The use of atypical antipsychotics and the risk of breast cancer. Breast Cancer Res Treat 2011; 129 (2): 541–8. 4. Berinder K, Akre O, Granath F, Hulting AL. Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol 2011; 165 (2): 209–15. 5. Biglia N, Torta R, Roagna R et al. Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas 2005; 52 (1): 78–85. 6. Boekhout AH, Vincent AD, Dalesio OB et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2011; 10 (29): 3862–8. 7. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic – induced hyperprolactinemia. Pharmacotherapy 2009; 29 (1): 64–73. 8. Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 2011; 12 (6): 570–7. 9. Chintamani C, Gogne A, Khandelwal R et al. The correlation of anxiety and depression levels with response to neoadjuvant chemotherapy in patients with breast cancer. JRSM Short Rep 2011; 2 (3): 15. 10. Costantini C, Ale-Ali A, Helsten T. Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. J Palliat Med 2011; 14 (5): 563–6. 11. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P-450 2D6. J Clin Psychiat 2009; 70 (12): 1688–97. 12. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6 (4): 278–96. 13. Harvey PW, Everett DJ, Springall CJ. Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol 2008; 22 (2): 20–7. 14. Haviland JS, Watson M, Greer S et al. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet 1999; 354: 1331–6. 15. Henry NL, Banerjee M, Wicha M et al. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer 2011; 117 (24): 5469–75. 16. Irarrázaval OM. Antagonism of tamoxifen and antidepressants among women with breast cancer. Rev Med Chil 2011; 139 (1): 89–99. 17. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97 (1): 30–9. 18. Kissane D. Beyond the psychotherapy and survival debate: the challenge of social disparity, depression and treatment adherence in psychosocial cancer care. Psychooncol 2009; 18 (1): 1–5. 19. Koga M, Nakadozono M, Nukariya K et al. Clonazepam for chemotherapy-induced nausea and vomiting (CINV). Anticancer Res 2008; 28 (4C): 2433–6. 20. Loprinzi CL, Pisansky TM, Fonseca R et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998; 16 (7): 2377–81. 21. Maguire P, Hopwood P, Tarrier N, Howell T. Treatment of depression in cancer patients. Acta Psychiat Scand (Suppl.) 1985; 320: 81–4. 22. McGuya W. Clinical Global Impression (CGI) In: ECDEU Assessment Manual for Psychopharmacol 1976; pp. 217–22. 23. Möslinger-Gehmayr R, Zaninelli R, Contu A. A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression. Zentralbl Gynakol 2000; 122 (4): 195–202. 24. Pachman DR, Jones JM, Loprinzi CL. Management of menopause-associated vasomotor symptoms: current treatment options, challenges and future directions. Int J Womens Health 2010; 9 (2): 123–35. 25. Pasquini M, Speca A, Biondi M. Quetiapine for tamoxifen-induced insomnia in women with breast cancer. Psychosomatics 2009; 50 (2): 159–61. 26. Ramani S, Karnad AB. Long-term subcutaneous infusion of midazolam for refractory delirium in terminal breast cancer. South Med J 1996; 89 (11): 1101–3. 27. Razavi D, Delvaux N, Farvacques C et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 1993; 11 (7): 1384–90. 28. Razavi D, Kormoss N, Collard A et al. Comparative study of the efficacy and safety of trazodone vs clorazepate in the treatment of adjustment disorders in cancer patients: a pilot study. J Int Med Res 1999; 27 (6): 264–72. 29. Roscoe JA, Morrow GR, Hickok JT et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 2005; 89 (3): 243–9. 30. Spiegel D. Cancer and depression. Br J Psychiat Suppl 1996; 30: 109–16. 31. Spiegel D, Gies-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiat 2003; 54 (3): 269–82. 32. Stearns V, Slack R, Greep N et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005; 1; 23 (28): 6919–30. 33. Tong FZ, Zhang JQ, Qiao XM et al. Effect of diazepam on delayed nausea and vomiting caused by anticancer agents. Gan To Kagaku Ryoho 1998; 25 (3): 391–5. 34. Tsavaris N, Kosmas C, Vadiaka M et al. Comparative study of tropisetron with the addition of dexamethasone or alprazolam in breast cancer patients receiving adjuvant chemotherapy with CEF (cyclophosphamide, epirubicin and 5-fluorouracil). J Chemother 2001; 13 (6): 641–7. 35. Watson M, Homewood J, Haviland J, Bliss JM. Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort. Eur J Cancer 2005; 41 (12): 1710–4. 36. Watson M, Kissane D. Handbook of psychotherapy in cancer care. UK: Wiley-Blackwell 2011. 37. Yonkers KA. Paroxetine treatment of mood disorders in women: premenstrual dysphoric disorder and hot flashes. Psychopharmacol Bull 2003; 37 (1): 135–47. 38. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiat Scand 1983; 67 (6): 361–70. 39. Zourková A, Hadasová E. Paroxetine-induced conversion of cytochrome P-450 2D6 phenotype and occurence of adverse effects. Gen Physiol Biophys 2003; 22 (1): 103–13.